局限期小细胞肺癌放化综合治疗疗效及临床预后因素  

Therapeutic Effect and Clinical Prognosis Factor of Limited-stage Small Cell Lung Cancer Treated with Chemotherapy Combined with Radiotherapy

作　　者：黄壬峰 彭少华 李有强 梁武 赵娜 HUANG Renfeng PENG Shaohua LI Youqiang LIANG Wu ZHAO Na.(Department of Radiotherapy ,Hainan Nongken General Hospital ,Haikou 570311, China)

机构地区：[1]海南省农垦总医院放疗科,海口570311

出　　处：《医学综述》2017年第1期171-173,178,共4页Medical Recapitulate

摘　　要：目的观察局限期小细胞肺癌(LS-SCLC)放化综合治疗的临床疗效,并对临床预后因素进行分析。方法选取2010年2月至2011年2月海南省农垦总医院收治的149例行放化综合治疗LS-SCLC患者为研究对象。对放化综合治疗临床预后相关因素进行分析。结果放化综合治疗局限期小细胞肺癌近期治疗有效率为90.6%(135/149)。放化综合治疗组中位生存期为28个月,多因素分析显示治疗前合并胸腔积液(OR=5.852,95%CI2.442~14.024)、肿瘤体积(OR=3.074,95%CI 1.522~6.209)、临床分期(OR=2.256,95%CI 1.054~4.829)是影响患者预后的独立危险因素(P<0.05)。结论 LS-SCLC放化综合治疗疗效好,合并胸腔积液、肿瘤体积较大、临床分期晚是影响患者预后的独立因素。Objective To investigate the clinical effect of chemotherapy combined with radiotherapy in the treatment of limited-stage small cell lung cancer （ LS-SCLC）, and to analyze the related factors of prognosis. Methods A total of 149 LS-SCLC patients treated with combined radiotherapy and chemotherapy in Hainan Nongken General Hospital from Feb. 2010 to Feb. 2011 were included in the study. The short term curative effect and the related factors of clinical prognosis were analyzed. Results Short-term treatment efficacy of combined therapy was 90. 6% （135/149）. The median survival time of patients receiving combined therapy was 28 months, and multiple-factor analysis showed that the patients with pleural effusion （ OR = 5. 852,95% CI 2. 442-14. 024 ）, tumor volume（ OR = 3.074,95% CI 1. 522-6. 209 ）, clinical stage （ OR = 2. 256,95 % CI I. 054-4. 829） were independent risk factors affecting the long-term survival rate （ P 〈 0. 05 ）. Conclusion The clinical effect of chemotherapy combined with radiotherapy in the treatment of LS-SCLC is good, and the independent factors affecting the prognosis of patients are pleural effusion, tumor size and clinical stage.

关 键 词：局限期小细胞肺癌 放疗 化疗 

分 类 号：R734.2[医药卫生—肿瘤]